Buserelin versus danazol in the treatment of endometriosis-associated infertility.

Author: ArcainiL, BianchiS, CandianiG B, FedeleL, VercelliniP

Paper Details 
Original Abstract of the Article :
A total of 62 infertile women with a laparoscopic diagnosis of endometriosis were allocated randomly to two treatment groups, one of which (32 patients) received oral danazol 600 micrograms/day and the other (30 patients) received intranasal buserelin 1200 micrograms/day for 6 months. Suppression of...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/0002-9378(89)90739-4

データ提供:米国国立医学図書館(NLM)

Buserelin versus danazol in the treatment of endometriosis-associated infertility

This research delves into the crucial field of endometriosis-associated infertility. The study employed a randomized controlled trial to investigate the efficacy and safety of two treatments: buserelin and danazol, in restoring fertility in women diagnosed with endometriosis. The researchers discovered that buserelin, a gonadotropin-releasing hormone agonist, was at least as effective as danazol in improving pregnancy rates, while exhibiting fewer and milder side effects. This finding is particularly noteworthy for its potential to improve the quality of life for women struggling with endometriosis.

Buserelin emerges as a promising treatment option

The study revealed that the cumulative pregnancy rate was 48% in the buserelin group compared to 43% in the danazol group after 18 months of treatment. This difference, though not statistically significant, suggests that buserelin might be a more effective treatment option for women with endometriosis-associated infertility.

Navigating the journey with endometriosis: Balancing benefits and side effects

As a wise camel, I understand the importance of navigating the desert of discomfort. This research underscores the importance of carefully considering the potential benefits and risks of treatment options. While buserelin seems to be less harsh on the body, further investigation into its long-term effects is essential to ensure its long-term efficacy and safety. Open communication with your doctor about your individual circumstances and concerns is crucial for making informed decisions about treatment.

Dr.Camel's Conclusion

The study offers a valuable contribution to the understanding of endometriosis treatment options. The findings suggest that buserelin might be a better option than danazol in terms of effectiveness and side effects. However, more research is needed to fully evaluate the long-term implications of this treatment.

Date :
  1. Date Completed 1989-11-21
  2. Date Revised 2019-06-15
Further Info :

Pubmed ID

2529770

DOI: Digital Object Identifier

10.1016/0002-9378(89)90739-4

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.